Bosutinib (BOS) vs imatinib (IM) for newly diagnosed chronic myeloid leukemia (CML): Initial results from the BFORE trial Meeting Abstract
| Authors: | Brümmendorf, T. H.; Gambacorti-Passerini, C.; Deininger, M.; Mauro, M. J.; Chuah, C.; Kim, D. W.; Le Coutre, P.; Jentsch-Ullrich, K.; Waller, C.; Wolf, D.; Reilly, L.; Jeynes-Ellis, A.; Leip, E.; Bardy-Bouxin, N.; Hochhaus, A.; Cortes, J. E. |
| Abstract Title: | Bosutinib (BOS) vs imatinib (IM) for newly diagnosed chronic myeloid leukemia (CML): Initial results from the BFORE trial |
| Meeting Title: | Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 40 |
| Issue: | Suppl. 3 |
| Meeting Dates: | 2017 Sep 29-Oct 3 |
| Meeting Location: | Stuttgart, Germany |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2017-09-01 |
| Start Page: | 121 |
| Language: | English |
| ACCESSION: | WOS:000411428400301 |
| PROVIDER: | wos |
| PUBMED: | 28934740 |
| DOI: | 10.1159/000479566 |
| Notes: | Meeting Abstract: V455 -- Source: Wos |
